FF Mobility Trading continues to strengthen its Middle East EAI robotics strategy through strategic cooperation frameworks and regional ecosystem collaboration across the UAE, GCC, and potentially the broader MENA region.
① FF Achieved Record First-Half Revenue, with Its Robotics Business Entering a New Phase of Volume Expansion and Accelerating Revenue Growth.
② In the Second Half, the Company Will Accelerate Revenue Growth Across Its Four-Core Full-Stack AI Ecosystem, Advance Phase Two of the "Built in USA" Program and Execute a Comprehensive Debt Resolution Plan, While Actively Exploring Independent Financing and Potential Public Listing Opportunities for the Robotics Business.
③ The August 26 and September 28 Upstream & Downstream Partner Recruitment Conferences Will Connect the Entire Industry Value Chain to Accelerate Nationwide Deployment of the "Built in USA" Initiative and the EAI Robotics Education Ecosystem.
learn more ：https://app-us.ff.com/ff-v3/news/1594?lang=en-US
Visa Q3 2026: A great business — but is the stock still a great investment?
Visa just reported its fiscal Q3 2026 results, and once again the underlying business continues to look incredibly resilient.
Consumer spending remains strong, and Visa continues to benefit from the long-term shift from cash toward digital payments.
What makes Visa particularly interesting to me is the business model. Visa doesn't take the same credit risk as a bank — it primarily earns money from the enormous amount of payment volume flowing through its network.
That creates a business with strong margins, recurring transaction-based revenue and a network effect that is extremely difficult to replicate.
But there is another side to the investment case.
Visa is already a massive company, and the market clearly understands the quality of the business. That means the key question isn't really whether Visa is a great company.
The question is whether you're paying too much for that quality.
There are also longer-term risks worth considering: regulation of interchange fees, alternative payment systems, stablecoins and whether new payment technologies could eventually weaken the traditional card networks.
At the same time, Visa itself is investing heavily in areas like stablecoins and AI rather than simply watching those changes happen.
I went through the latest earnings, growth assumptions, risks and valuation in my latest analysis:
Would you buy Visa at today's valuation, or does the price already reflect too much of the company's quality?
Disclosure: I [own/do not own] shares in Visa.
AI disclosure: AI was used to assist with editing and structuring this post. The analysis, assumptions and conclusions are my own.
$NCRA News August 11, 2026
Nocera and INERGX Form 50/50 Joint Venture to Acquire and Consolidate the Mission-Critical Energy Supply Chain Serving AI Data Centers, Defense & Heavy Industry, Targeting a $250 Million Valuation for INERGX
https://finance.yahoo.com/energy/articles/nocera-inergx-form-50-50-120000721.html
Novo Nordisk Q2 2026: Better numbers, but the market is still worried
Novo Nordisk just reported Q2, and I think the reaction is more interesting than the headline numbers.
Adjusted operating profit came in at DKK 33.4B, up 11% YoY, and management raised its 2026 outlook. Adjusted sales and operating profit growth are now expected to be between 0% and -6% at constant exchange rates.
So why did the stock still struggle?
The market seems much more focused on what happens after the current semaglutide franchise.
Oral Wegovy generated DKK 3.22B in sales. That's strong for a relatively new launch, but slightly below expectations.
More importantly, competition with Eli Lilly remains intense. CagriSema has also failed to establish the clear advantage over tirzepatide that investors once hoped for.
To me, that creates an interesting valuation question:
How much of Novo's current valuation reflects temporary problems and how much reflects a genuine deterioration in its long-term competitive position?
I went through the Q2 numbers, growth assumptions, risks and valuation in my latest analysis:
Curious what others think: Is Novo becoming attractive at these levels, or does Lilly's momentum justify the discount?
AI disclosure: AI was used to assist with editing and structuring this post. The analysis, assumptions and conclusions are my own.